Evidence linked upregulation of KEAP1 expression with increased levels of the BET protein BRD4, and with concomitant downregulation of NRF2 in prostate cancer cell lines, where integration of RNA-seq data with chromatin immunoprecipitation (ChIP) assays correlated NRF2-dependent gene expression with KEAP1 among the top genes interacting with BRD4 [45]. This evidence concerns the gene BRD4 and prostate carcinoma.